AMPH vs PGNY: fair value comparison
Amphastar Pharmaceuticals, Inc. and Progyny, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, PGNY currently sits closer to the top of our discount ranking. PGNY carries the stronger quality grade.
| AMPH | PGNY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $22.96 | $25.66 |
| 12-month range | $18.42–$27.92 | $16.86–$31.53 |
| Sector rank | #26 of 113 Healthcare | #21 of 113 Healthcare |
| Quality grade | B | A |
| Momentum grade | A | — |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Expanding |
| Revenue growth | Modest | Modest |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: AMPH fair value analysis · PGNY fair value analysis